White House strikes deals for lower prices on obesity drugs

Sydney Lupkin

November 06, 2025 / 11:00 am

People who rely on Medicare for their health insurance will soon be able to get blockbuster obesity and Type 2 diabetes drugs with $50 monthly copays under two new deals the Trump administration announced Thursday.

President Trump and his team announced the deals with Novo Nordisk, which makes Ozempic and Wegovy, and Eli Lilly, which makes Mounjaro and Zepbound, from the Oval Office.

The deals are part of a broader initiative the administration calls most-favored-nation drug pricing, which is an attempt to lower American drug prices, and get the same or lower prices as other developed countries.

"We believe these deals, within two years … based on our health improvements, we will

See Full Page